Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis

Gynecological Endocrinology

Volumn 23, Issue 7, 2007, Pages 398-403

  Dane, Cem ^a,b   Dane, Banu ^a   Cetin, Ahmet ^a   Erginbas, Murat ^a  

^a HASEKI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b NONE   (Turkey)

Author keywords

Bone mineral density; Bone turnover; C terminal telopeptide fragment of type I collagen; Low dose hormone replacement therapy; Osteocalcin; Postmenopausal osteoporosis; Raloxifene

Indexed keywords

BIOLOGICAL MARKER; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; NORETHISTERONE ACETATE; OSTEOCALCIN; RALOXIFENE; VITAMIN D;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; FEMALE; HORMONE SUBSTITUTION; HUMAN; LOW DRUG DOSE; LUMBAR SPINE; MEASUREMENT; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COLLAGEN TYPE I; DRUG COMBINATIONS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; NORETHINDRONE; OSTEOCALCIN; OSTEOPOROSIS; PEPTIDES; POSTMENOPAUSE; RALOXIFENE;

EID: 34548142605     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590701414907     Document Type: Article

References (31)

1. Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137-1141.
2. Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy I: a 10-year prospective study in relationship to osteoporosis. Obstet Gynecol 1979;53:277-281.
3. Tepper R, Goldberger S, Cohen I, Segal J, Yarkoni S, Fejgin M, Beyth Y. Estrogen replacement in post-menopausal women: are we currently overdosing our patients? Gynecol Obstet Invest 1994;38:113-116.
4. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75:1065-1079.
5. Pickar JH, Yeh I, Wheeler JE, Cunnane MF, Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;76:25-31.
6. Lobo RA, Bush T, Carr BR, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 2001;76:13-24.
7. Gambacciani M, Monteleone P, Genazzani AR. Low-dose hormone replacement therapy: effects on bone. Climacteric 2002;5:135-139.
8. Mizunuma H, Okano H, Soda M, Kagami I, Miyamoto S, Tokizawa T, Honjo S, Ibuki Y. Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: a 2-year prospective study. Maturitas 1997;27:69-76.
9. Gambacciani M, Ciaponi M, Cappagli B, Monteleone P, Benussi C, Bevilacqua G, Genazzani AR. Postmenopausal femur bone loss: effects of a low dose hormone replacement therapy. Maturitas 2003;45:175-183.
10. van de Weijer PH, Mattsson LA, Ylikorkala O. Benefits and risks of long-term low-dose oral continuous combined hormone therapy. Maturitas 2007;56:231-248.
11. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-333.
12. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
13. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. J Am Med Assoc 1999;281:2189-2197.
14. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat 2001;65:125-134.
15. Meunier PJ, Vignot E, Garnero P, Confavreux E, Paris E, Liu-Leage S, Sarkar S, Liu T, Wong M, Draper MW. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Osteoporos Int 1999;10:330-336.
16. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. J Am Med Assoc 1999;282:637-645.
17. Altkorn D, Vokes T. Treatment of postmenopausal osteoporosis. J Am Med Assoc 2001;285:1415-1418.
18. Delmas PD, Confavreux E, Garnero P, Fardellone P, de Vernejoul MC, Cormier C, Arce JC. A combination of low doses of 17β-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women. Osteoporos Int 2000;11:177-187.
19. Greenwald MW, Gluck OS, Lang E, Rakov V. Oral hormone therapy with 17β-estradiol and 17β-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects. Menopause 2005;12:741-748.
20. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-1647.
21. Morii H, Ohashi Y, Taketani Y, Fukunaga M, Nakamara T, Itabashi A, Sarkar S, Harper K. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial. Osteoporosis Int 2003;14:793-800.
22. Johnston CC Jr, Bjarnason NH, Cohen FJ, Shah A, Lindsay R, Mitlak BH, Huster W, Draper W, Harper KD, Heath H 3rd, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 2000;160:3444-3450.
23. Michalska D, Stepan JJ, Basson BR, Pavo I. The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2006;91:870-877.
24. Prestwood KM, Gunness M, Muchmore DB, Lu Y, Wong M, Raisz LG. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab 2000;85:2197-2202.
25. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996;11:835-842.
26. Ravn P, Bidstrup M, Wasnich RD, Davis JW, McClung MR, Balske A, Coupland C, Sahota O, Kaur A, Daley M, et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med 1999;131:935-942.
27. Marcus R, Holloway L, Wells B, Greendale G, James MK, Wasilauskas C, Kelaghan J. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. J Bone Miner Res 1999;14:1583-1595.
28. Tsai KS, Yen ML, Pan HA, Wu MH, Cheng WC, Hsu SH, Yen BL, Huang KE. Raloxifene versus continuous combined estrogen/progestin therapy: densitometric and biochemical effects in healthy postmenopausal Taiwanese women. Osteoporos Int 2001;12:1020-1025.
29. Reid IR, Eastell R, Fogelman I, Adachi JD, Rosen A, Netelenbos C, Watts NB, Seeman E, Ciaccia AV, Draper MW. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Arch Intern Med 2004;164:871-879.
30. Peeyananjarassri K, Baber R. Effects of low-dose hormone therapy on menopausal symptoms, bone mineral density, endometrium, and the cardiovascular system: a review of randomized clinical trials. Climacteric 2005;8:13-23.
31. Weinstein RS, Parfitt AM, Marcus R, Greenwald M, Crans G, Muchmore DB. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Osteoporosis Int 2003;14:814-822.